AMAG Pharmaceuticals $700 million acquisition of Cord Blood Registry

Overview:

• AMAG Pharmaceuticals has completed its $700 million cash acquisition of Cord Blood Registry.
• Cord Blood Registry stores more than 600,000 umbilical cord blood and tissue cells, and its purchase is part of a move to focus on maternal and regenerative health products by AMAG.
• The deal was originally announced June 29 2015.
• CBR was sold to AMAG by private equity firm GTCR.
• Jefferies Finance and Barclays provided financing for the acquisition.
• Goodwin Procter (Stuart Cable, Joe Bernardi) advised AMAG.
• Kirkland & Ellis (Sanford Perl, Michael Weed) advised CBR and GTCR.
• Jones Day advised the lenders.

Kurt Stumpo - Journalist - North America and the Caribbean